Skip to content
IP + Technology Law
Home  »  News & Insights  »  News

Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States

October 20, 2014  | Joseph Mallon, Ph.D., Ryan E. Melnick, Ph.D., Kimberly J. Miller, Ph.D., Agnes Juang, Ph.D., Kerry S. Taylor, Ph.D., William Zimmerman, Rose M. Thiessen, Ph.D., Jing Liu, Jane Dai, Ph.D., Nathanael Luman, Ph.D., Victor C. Vassar and Vijay Gore, Ph.D.

Read the full press release here.

Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Joseph Mallon, Ph.D.
Partner
San Diego
joseph.mallon@knobbe.com
858-707-4000
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Ryan E. Melnick, Ph.D.
Partner
San Diego
ryan.melnick@knobbe.com
858-707-4000
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Kimberly J. Miller, Ph.D.
Partner
San Diego
kimberly.miller@knobbe.com
858-707-4000
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Agnes Juang, Ph.D.
Partner
Orange County
agnes.juang@knobbe.com
949-760-0404
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

William Zimmerman
Partner
Washington DC
bill.zimmerman@knobbe.com
202-640-6400
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Jane Dai, Ph.D.
Partner
San Diego
jane.dai@knobbe.com
858-707-4000
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Nathanael Luman, Ph.D.
Partner
San Diego
nate.luman@knobbe.com
858-707-4000

Related Links

Industries

News & Insights

News
May 2026
Three Knobbe Martens Partners Named Among Top IP Lawyers in California by Daily Journal
Sheila Swaroop, Brian Horne and Joseph Re recognized for strength in intellectual property litigation IRVINE, Calif., May 20, 2026 – Reflecting the firm’s strengths in high-stakes litigation, Knobbe Martens is...
Blog - Medical Devices & Procedures
Apr 2026
Protaryx Receives FDA Approval for Transseptal Puncture Device
Protaryx Medical, a Maryland-based company dedicated to “minimally invasive left-heart interventional therapies,” announced that its Transseptal Puncture Device received 510(k) clearance from the FDA. Transseptal puncture is designed to enable access to...
News
Apr 2026
Knobbe Martens Receives Firm of the Year, Litigation Honors at 2026 Managing IP Americas Awards
IRVINE, Calif., April 10, 2026 – Knobbe Martens is proud to announce that the firm received multiple recognitions at the 2026 Managing IP Awards, including “IP Boutique Firm of the...